Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL28225544 | 0.89 | ALDH1A1 (0.64) | TSHRSIGMAR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL13952 | 0.88 | SIGMAR1 (0.81) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| SCHEMBL1777747 | 0.88 | SIGMAR1 (0.81) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| Acetic Acid SCHEMBL7594626 | 0.87 | ALDH1A1 (0.62) | TSHRSIGMAR1ALDH1A1KMT2AMEN1 | |
| Bromide SCHEMBL10447698 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| SCHEMBL688047 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| SCHEMBL11141692 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| SCHEMBL8327 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| SCHEMBL11585348 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA | |
| Ammonia Solution, Strong SCHEMBL3699405 | 0.86 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1HRH3CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005047293-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176738-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | TSHR 45/4885SIGMAR1 56/4885ALDH1A1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.